This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Peter Hong
Peter Hong
New York +1 212 841 1182 Download V-card

Peter Hong's practice includes mergers and acquisitions and corporate and securities law, with a focus on capital markets transactions. He also advises clients on corporate governance and other general corporate matters.

  • Represented the underwriters in the $161 million initial public offering of a biopharmaceutical company that develops novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders.
  • Represented the underwriters in multiple public offerings of a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
  • Represented the underwriters in the $46 million follow-on public offering of an emerging specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceutical products and technologies.
  • Represented a global pharmaceutical company in its $1.7 billion acquisition of a clinical-stage biopharmaceutical company that develops therapies for challenging disorders of the central nervous system.